Close Menu

NEW YORK ─ Luminex on Wednesday announced preliminary financial results for the second quarter of 2020, saying it anticipates revenues would increase more than 30 percent over Q2 2019, driven by pandemic-related sales across all respiratory and COVID-19 products.

For the three months ended June 30, the molecular diagnostics firm said its revenues would be between $109 million and $110 million compared to the $83.1 million that it reported for the prior-year quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.